Previous close | 8.59 |
Open | 8.57 |
Bid | 0.00 x 900 |
Ask | 0.00 x 800 |
Day's range | 8.45 - 8.74 |
52-week range | 3.38 - 8.99 |
Volume | |
Avg. volume | 445,369 |
Market cap | 549.128M |
Beta (5Y monthly) | 0.08 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.54 |
Earnings date | 04 Nov 2021 - 08 Nov 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 14.29 |
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right...
Key Insights Institutions' substantial holdings in Liquidia implies that they have significant influence over the...
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 0% and 8.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
You may think that with a price-to-sales (or "P/S") ratio of 28.5x Liquidia Corporation ( NASDAQ:LQDA ) is a stock to...
Liquidia Corporation ( NASDAQ:LQDA ) shareholders will have a reason to smile today, with the analysts making...
Liquidia ( NASDAQ:LQDA ) Full Year 2022 Results Key Financial Results Revenue: US$15.9m (up 24% from FY 2021). Net...
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 47.06% and 46.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Last week, Liquidia Corporation ( NASDAQ:LQDA ) insiders, who had purchased shares in the previous 12 months were...
Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
The average of price targets set by Wall Street analysts indicates a potential upside of 153.2% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here is how Acadia Healthcare (ACHC) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.
Potential Liquidia Corporation ( NASDAQ:LQDA ) shareholders may wish to note that the CEO & Director, Roger Jeffs...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
One of the more volatile healthcare stocks of recent days, Liquidia Technologies (NASDAQ: LQDA), had quite the up session on Friday. Investors lifted the share price of the drug developer by almost 21%, following a series of relatively small but confidence-boosting insider buys. Liquidia has been an up-and-down stock due to developments on the legal front, specifically a patent infringement dispute it was engaged in against plaintiff United Therapeutics (NASDAQ: UTHR).
The mean of analysts' price targets for Liquidia Technologies, Inc. (LQDA) points to a 136.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how Liquidia Technologies, Inc. (LQDA) and PolyPid Ltd. (PYPD) have performed compared to their sector so far this year.
We used one of our Zacks screens to help show investors how to find strong, highly-ranked stocks that are trading for under $10 per share to consider buying as we start to close out August.
Does Liquidia Technologies, Inc. (LQDA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Shares of Liquidia Technologies (NASDAQ: LQDA), a biopharmaceutical company specializing in treatment of pulmonary arterial hypertension and other uses of its PRINT (Particle Replication In Non-Wetting Templates) technology, rose 18.4% on Monday. The stock closed at $7.30 on Friday, then rose to a high of $8.64 on Monday before falling to $8.39 at Monday's close. The stock has a 52-week low of $2.40 with a high of $8.79.
The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.